Accordingly, we investigated possible interactions between use of SGLT2 inhibitors and the increase in haemoglobin in patients randomized to intravenous iron or the control group in the IRONMAN (Effectiveness of Intravenous Iron Treatment versus Standard Care in Patients with Heart Failure and Iron Deficiency) trial. The gene discussed is SLC5A2; the disease is Iron deficiency anemia.